Session: SUN 130-162-Neuroendocrinology
Poster Board SUN-149
Objective:To assess QoL over 10 years in adult patients with childhood onset (CO) and adult onset (AO) GHD who received GH replacement in HypoCCS.
Patients and methods: 1646 GH-treated patients with AO GHD [age (yr): 49.2 ± 12.4 (mean ± SD), 51% male] and 361 patients with CO GHD (28.2 ± 9.0, 55% male) who had available QoL data at study entry were included in this analysis. QoL was measured by a disease-specific instrument, Questions on Life Satisfaction-Hypopituitarism (QLS-H), in these patients from 7 countries (France, Germany, Italy, the Netherlands, Spain, UK and the USA), where validated questionnaires and normative data for calculation of Z-scores were available (3,4). ANOVA was used for Z-score comparison.
Results: At study entry, patients had diminished QoL. AO patients had a lower Z-score than CO (-1.5 ± 1.7 vs. -0.9 ± 1.3, P <.001), and female (F) patients lower than male (M) (-1.7 ± 1.7 vs. -1.2 ± 1.5, P <.001). The largest QoL improvements were seen in the first year (yr): Z-score increased by 0.7 ± 1.4 for AO (P <.001), 0.5 ± 1.2 for CO (P <.001), 0.8 ± 1.5 for F (P <.001), and 0.6 ± 1.2 for M (P <.001). The initial improvement from study entry remained statistically significant throughout 10 yrs for AO, yrs of 1 to 7 and 9 for CO, yrs 1 to 10 for M, and yrs 1 to 9 for F (P <.05). The improvement was observed in all other yrs (yrs of 8 and 10 for CO and yr 10 for F), but did not reach statistical significance possibly due to small numbers of patients with available Z-scores in the later years. The mean Z-scores during follow up years varied from -0.9 to -0.8 in AO patients, -0.5 to 0.2 in CO patients, -1.2 to -0.8 in females, and -0.8 to -0.5 in males. For AO patients, the Z-scores for females (range -1.2 to -1.0) were significantly lower than for males (-0.8 to -0.5) in the first 9 yrs (P<.05).
Conclusion: These data suggest that GH replacement maintains an improvement of QoL toward normality over a period of up to 10 years.
Disclosure: DM: Employee, Eli Lilly & Company, Employee, Eli Lilly & Company. WFB: Employee, Eli Lilly & Company, Employee, Eli Lilly & Company. MR: Employee, Eli Lilly & Company, Employee, Eli Lilly & Company. RJR: Founder, Diurnal. Nothing to Disclose: AFA, SMW, CJS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters